Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
Philip J. Mease, Iain B. McInnes, Lai‐Shan Tam, et al.
Lara D. Veeken (2021) Vol. 60, Iss. 5, pp. 2109-2121
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis
Daniel Wendling, Sophie Hecquet, O. Fogel, et al.
Joint Bone Spine (2022) Vol. 89, Iss. 3, pp. 105344-105344
Open Access | Times Cited: 81
Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies
Nicolò Costantino Brembilla, Wolf‐­Henning Boehncke
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 44
IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy
James G. Krueger, Kilian Eyerich, Vijay K. Kuchroo, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 17
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
Laura C. Coates, Laure Gossec, Elke Theander, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 3, pp. 359-369
Open Access | Times Cited: 69
Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes
Iain B. McInnes, L. Sawyer, Kristen Markus, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002074-e002074
Open Access | Times Cited: 48
Inflammatory Cytokines in Psoriatic Arthritis: Understanding Pathogenesis and Implications for Treatment
Bong-Woo Lee, Su‐Jin Moon
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11662-11662
Open Access | Times Cited: 31
Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials
Xiaojing Huang, Haojie Shentu, Yujing He, et al.
Immunologic Research (2023) Vol. 71, Iss. 4, pp. 505-515
Open Access | Times Cited: 20
Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 2 «Manejo de poblaciones especiales, pacientes con comorbilidad y gestión del riesgo»
J.M. Carrascosa, L. Puig, I. Belinchón, et al.
Actas Dermo-Sifiliográficas (2022) Vol. 113, Iss. 6, pp. 583-609
Open Access | Times Cited: 23
Osteoarthritis versus psoriasis arthritis: Physiopathology, cellular signaling, and therapeutic strategies
Salma Nassor Juma, Junguang Liao, Yuping Huang, et al.
Genes & Diseases (2023) Vol. 11, Iss. 3, pp. 100986-100986
Open Access | Times Cited: 16
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023
Kevin Winthrop, Philip J. Mease, Andreas Kerschbaumer, et al.
Annals of the Rheumatic Diseases (2023) Vol. 83, Iss. 4, pp. 409-416
Open Access | Times Cited: 15
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis
Philip J. Mease, Dafna D. Gladman, Joseph F. Merola, et al.
Lara D. Veeken (2024) Vol. 63, Iss. 7, pp. 1779-1789
Open Access | Times Cited: 5
Janus kinase inhibitors for psoriatic arthritis: Evidence from a systematic review and network meta-analysis
Sotirios G. Tsiogkas, Arriana Gkouvi, Katerina‐Maria Kontouli, et al.
Autoimmunity Reviews (2025), pp. 103819-103819
Open Access
Artritis psoriásica
A. López‐Ferrer, A. Laíz, L. Puig
Medicina Clínica (2022) Vol. 159, Iss. 1, pp. 40-46
Closed Access | Times Cited: 17
Current and emerging prospects in the psoriatic treatment
Rutuja Vilas Nikam, M Gowtham, Pratiksha Sanjay More, et al.
International Immunopharmacology (2023) Vol. 120, pp. 110331-110331
Closed Access | Times Cited: 10
Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities
Laura Mateu Arrom, L. Puig
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 4, pp. 363-379
Closed Access | Times Cited: 3
Biologics in the treatment of active Psoriatic arthritis in China: a network meta-analysis and cost-effectiveness analysis
Ouyang Xie, Mei-Yu Wu, Andong Li, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2025), pp. 1-9
Closed Access
Sequential biologic therapy in the treatment of active psoriatic arthritis in China: a cost-effectiveness analysis
Ouyang Xie, Mei-Yu Wu, Andong Li, et al.
Clinical Rheumatology (2025)
Closed Access
Efficacy of Biological or Targeted Synthetic Disease‐Modifying Anti‐Rheumatic Drugs in Active Psoriatic Arthritis: A Network Meta‐Analysis of Randomized Controlled Trials
Siming Gao, Hui Song
Journal of Clinical Pharmacy and Therapeutics (2025) Vol. 2025, Iss. 1
Open Access
The Saudi consensus recommendations for the management of psoriatic arthritis (2023)
Ibrahim A. Al-Homood, Nayef Al Ghanim, Mohammad I. Fatani, et al.
Clinical Rheumatology (2024) Vol. 43, Iss. 3, pp. 879-894
Open Access | Times Cited: 2
IL-12 family cytokines and autoimmune diseases : A potential therapeutic target?
Xue Shi Cui, Wu Liu, Hanxue Jiang, et al.
Journal of Translational Autoimmunity (2024) Vol. 10, pp. 100263-100263
Open Access | Times Cited: 2
Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience
Federico Bardazzi, Filippo Viviani, Yuri Merli, et al.
Expert Opinion on Biological Therapy (2022) Vol. 22, Iss. 12, pp. 1561-1566
Closed Access | Times Cited: 11
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis
Laura C. Coates, Christopher T. Ritchlin, Laure Gossec, et al.
Lara D. Veeken (2022) Vol. 62, Iss. 2, pp. 606-616
Open Access | Times Cited: 10
Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis
Philip J. Mease, Iain B. McInnes, Lai‐Shan Tam, et al.
Lara D. Veeken (2022) Vol. 62, Iss. 4, pp. 1417-1425
Open Access | Times Cited: 10
Guselkumab for treating immune checkpoint inhibitor-induced psoriatic arthritis
Koichi Takeda, Noriko Yanagitani
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 10, pp. 1479-1480
Closed Access | Times Cited: 9
Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group
Vicenç Rocamora, Laura Crespí, Marta Ferrán, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 11
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top